Publications by authors named "Mark J Messing"

Claim this Profile
E
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.
Vicky Makker, Matthew H Taylor, Carol Aghajanian, Allen L Cohn, Marcia S Brose, Mark J Messing

J Immunother Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.
Michael Friedlander, Kenneth C Hancock, Danny Rischin, Mark J Messing, Claude A Stringer

Gynecol Oncol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
Michael G Teneriello, Paul C Tseng, Mark Crozier, Carlos Encarnacion, Kenneth Hancock, Mark J Messing

J Clin Oncol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
Alan N Gordon, Lina Asmar, Mark J Messing, Daron G Street, Charles H Pippitt

Gynecol Oncol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis